Deriving safe limits for N-nitroso-bisoprolol by error-corrected next-generation sequencing (ecNGS) and benchmark dose (BMD) analysis, integrated with QM modeling and CYP-docking analysis

[chrischar]

Dear Mark,
for more information on this please look at the following position paper

EFPIA Position paper for NDSRIs of beta-blockers and beta-agonists / ACE inhibitors / dihydropyridine

Dear all, I would like to share this interesting EFPIA document about a possible interim AI for the beta-blockers and beta-agonists category. Here the conclusion: In conclusion, a weight of evidence approach, together with the understanding that NDSRIs such as nitrosamines of β -blockers are structurally very different than the small potent nitrosamines that are currently being used as the default surrogates for setting AIs for nitrosamines, leads to the conclusion that nitrosamines of β -bloc…

hope it helps,
best regards
Christos